The effects of hyperbaric oxygen therapy on the brain with middle cerebral artery occlusion

J Cell Physiol. 2021 Mar;236(3):1677-1694. doi: 10.1002/jcp.29955. Epub 2020 Jul 21.

Abstract

Middle cerebral artery occlusion (MCAO) causes focal cerebral hypoperfusion, resulting in cerebral ischemia or ischemic stroke. The main therapeutic approach is to restore an adequate blood flow to the brain via the process of reperfusion. However, rapid reperfusion can itself aggravate brain damage; this adverse effect is known as ischemic/reperfusion (I/R) injury. The pathological conditions that occur after cerebral ischemia and cerebral I/R are microvascular injury, blood-brain barrier dysfunction, post-ischemic inflammation, increased oxidative stress/reactive oxygen species, and a reduction in neuronal survival, leading to brain infarction. Animal and clinical studies on hyperbaric oxygen therapy (HBOT) have recently been carried out, and there is evidence of positive effects on neurological outcomes after cerebral ischemia. However, some evidence has shown that HBOT may not affect the functional recovery after ischemic injury. This review describes the current evidence, both in vivo and clinical data, regarding the potential benefits of HBOT after MCAO and cerebral I/R injury. The contrary data are also discussed to verify the effectiveness of HBOT in stroke outcomes.

Keywords: cerebral ischemia/reperfusion injury; hyperbaric oxygen therapy; middle cerebral artery occlusion; stroke.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Brain / pathology*
  • Humans
  • Hyperbaric Oxygenation*
  • Infarction, Middle Cerebral Artery / therapy*
  • Inflammation / pathology
  • Oxidative Stress
  • Stroke / therapy